Kolon Life Science Inc
KOSDAQ:102940
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kolon Life Science Inc
Change in Working Capital
Kolon Life Science Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Kolon Life Science Inc
KOSDAQ:102940
|
Change in Working Capital
-₩37.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Change in Working Capital
-₩109B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-23%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Change in Working Capital
-₩55.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Change in Working Capital
-₩212.2B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-2%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Change in Working Capital
-₩17B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-6%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Change in Working Capital
-₩21.9B
|
CAGR 3-Years
32%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Kolon Life Science Inc
Glance View
KOLON Life Science, Inc. engages in the manufacture and sale of pharmaceuticals and environment materials. The company is headquartered in Seoul, Seoul and currently employs 451 full-time employees. The company went IPO on 2009-04-07. The firm operates its business under two segments. The Chemical Business segment produces and sells raw drug products, which are the raw materials of new drugs and generic drugs, antibacterial agents that suppress bacterial growth, water treatment agents for environmental purification, and functional material products for cosmetics. The Bio Business segment manufactures and sells bio new medicines based on cell gene therapy products.
See Also
What is Kolon Life Science Inc's Change in Working Capital?
Change in Working Capital
-37.4B
KRW
Based on the financial report for Dec 31, 2025, Kolon Life Science Inc's Change in Working Capital amounts to -37.4B KRW.
What is Kolon Life Science Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
0%
Over the last year, the Change in Working Capital growth was -494%.
